Literature DB >> 16246435

Glia: novel counter-regulators of opioid analgesia.

Linda R Watkins1, Mark R Hutchinson, Ian N Johnston, Steven F Maier.   

Abstract

Development of analgesic tolerance and withdrawal-induced pain enhancement present serious difficulties for the use of opioids for pain control. Although neuronal mechanisms to account for these phenomena have been sought for many decades, their bases remain unresolved. Within the past four years, a novel non-neuronal candidate has been uncovered that opposes acute opioid analgesia and contributes to development of opioid tolerance and tolerance-associated pain enhancement. This novel candidate is spinal cord glia. Glia are important contributors to the creation of enhanced pain states via the release of neuroexcitatory substances. New data suggest that glia also release neuroexcitatory substances in response to morphine, thereby opposing its effects. Controlling glial activation could therefore increase the clinical utility of analgesic drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16246435     DOI: 10.1016/j.tins.2005.10.001

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  108 in total

1.  Involvement of spinal microglial P2X7 receptor in generation of tolerance to morphine analgesia in rats.

Authors:  Dong Zhou; Meng-Ling Chen; Yu-Qiu Zhang; Zhi-Qi Zhao
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

Review 2.  Roles of reactive oxygen and nitrogen species in pain.

Authors:  Daniela Salvemini; Joshua W Little; Timothy Doyle; William L Neumann
Journal:  Free Radic Biol Med       Date:  2011-01-28       Impact factor: 7.376

3.  Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.

Authors:  Suneeta Tumati; Tally M Largent-Milnes; Attila I Keresztes; Takashi Yamamoto; Todd W Vanderah; William R Roeske; Victor J Hruby; Eva V Varga
Journal:  Eur J Pharmacol       Date:  2012-06-05       Impact factor: 4.432

4.  Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.

Authors:  Suneeta Tumati; Tally M Largent-Milnes; Attila Keresztes; Jiyang Ren; William R Roeske; Todd W Vanderah; Eva V Varga
Journal:  J Neuroimmunol       Date:  2012-01-30       Impact factor: 3.478

5.  Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.

Authors:  Ai-Ling Li; Xiaoyan Lin; Amey S Dhopeshwarkar; Ana Carla Thomaz; Lawrence M Carey; Yingpeng Liu; Spyros P Nikas; Alexandros Makriyannis; Ken Mackie; Andrea G Hohmann
Journal:  Mol Pharmacol       Date:  2018-11-30       Impact factor: 4.436

6.  Herpes simplex virus vector-mediated expression of interleukin-10 reduces below-level central neuropathic pain after spinal cord injury.

Authors:  Darryl Lau; Steven E Harte; Thomas J Morrow; Shiyong Wang; Marina Mata; David J Fink
Journal:  Neurorehabil Neural Repair       Date:  2012-05-15       Impact factor: 3.919

Review 7.  Toll-like receptors in chronic pain.

Authors:  Lauren Nicotra; Lisa C Loram; Linda R Watkins; Mark R Hutchinson
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

8.  Possible role of spinal astrocytes in maintaining chronic pain sensitization: review of current evidence with focus on bFGF/JNK pathway.

Authors:  Ru-Rong Ji; Yasuhiko Kawasaki; Zhi-Ye Zhuang; Yeong-Ray Wen; Isabelle Decosterd
Journal:  Neuron Glia Biol       Date:  2006-11

9.  Expression of fractalkine and fractalkine receptor in urinary bladder after cyclophosphamide (CYP)-induced cystitis.

Authors:  Ruhin Yuridullah; Kimberly A Corrow; Susan E Malley; Margaret A Vizzard
Journal:  Auton Neurosci       Date:  2006-05-02       Impact factor: 3.145

10.  Morphine-enhanced apoptosis in selective brain regions of neonatal rats.

Authors:  Dusica Bajic; Kathryn G Commons; Sulpicio G Soriano
Journal:  Int J Dev Neurosci       Date:  2013-03-07       Impact factor: 2.457

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.